After Novartis Pact, Macrocycle Shop Unnatural Products Gets $45M Series B

Why It Matters

The infusion of growth capital positions Unnatural Products to fast‑track novel macrocycle candidates, potentially expanding treatment options for undruggable targets and strengthening Novartis’s pipeline.

Key Takeaways

• $45M Series B led by strategic biotech investors.
• Novartis partnership validates macrocycle platform.
• Funding targets IND‑enabling studies for lead candidates.
• Macrocycles address previously undruggable protein targets.
• Company expands team and synthesis capacity.

Pulse Analysis

The macrocycle renaissance is reshaping small‑molecule drug discovery. Unlike traditional linear compounds, macrocycles can simultaneously engage large, flat protein surfaces, opening therapeutic avenues for targets once deemed undruggable such as transcription factors and protein‑protein interactions. Advances in computational modeling, high‑throughput synthesis, and permeability engineering have lowered historical barriers, prompting major pharma and venture capital to pour capital into niche players. As the market anticipates a wave of first‑in‑class macrocycle candidates, companies that can de‑risk chemistry and biology are becoming strategic assets.

Unnatural Products, a 50‑person biotech out of Santa Cruz, leveraged a newly inked collaboration with Novartis to close a $45 million Series B round. The partnership gives Novartis early access to the firm’s proprietary macrocycle library and a co‑development option on up to three preclinical programs. The fresh capital will fund expansion of the company’s automated synthesis platform, accelerate IND‑enabling toxicology, and recruit additional medicinal chemists and pharmacologists. Management expects the first IND filing within 18 months, positioning the firm for a potential out‑licensing or joint‑venture milestone.

The infusion of growth capital signals broader confidence that macrocycles can fill gaps in existing therapeutic portfolios. For investors, Unnatural Products offers a clear path to value creation through milestone payments, royalty streams, and eventual exit opportunities. For the industry, the Novartis alliance validates the commercial relevance of macrocycle platforms and may spur further collaborations across oncology, immunology, and rare diseases. If the company meets its development timeline, it could accelerate the entry of first‑in‑class macrocycle drugs, reshaping how biotech addresses the most challenging disease targets.